Medcast raises $5.4 million for clinical AI platform
Best Practice SoftwareCompany
Medcast announced a $5.4 million venture round led by Best Practice Software to accelerate its AI‑driven clinical knowledge platform MedLuma, aiming to embed the tool in Australian general‑practice software.
Deal Terms
Medcast secured US$5.4 million (A$5.4 million) in a venture round closed on September 25, 2026. The round was led by Queensland‑based Best Practice Software, a veteran medical‑software provider that will also act as a strategic partner. The capital is earmarked for expanding the technology and clinical teams, accelerating product development, and integrating MedLuma with existing practice‑management solutions.
Strategic Rationale
The funding underwrites Medcast’s push to position MedLuma as an AI copilot for Australian GPs. The platform surfaces evidence‑based answers drawn from local guidelines and medical literature, with citations that keep clinicians within a trusted information loop. By keeping health data onshore and coupling algorithmic checks with human review, Medcast aims to overcome the trust barrier that has slowed adoption of generic AI search tools in clinical settings.
Founded in 2013 in Bowral, Medcast has already delivered education and professional‑development content to more than 100,000 registered health professionals. Earlier this year it launched MedLuma, initially targeting general practitioners with a focus on speed, relevance, and compliance with Australian practice standards. The new round will allow the company to deepen its clinical content partnerships, broaden its engineering headcount, and embed the AI engine directly into Best Practice’s practice‑management suite.
The partnership leverages Best Practice’s extensive footprint in Australian clinics, giving MedLuma immediate distribution channels and a built‑in feedback loop from real‑world users. For Medcast, the deal reduces go‑to‑market friction and accelerates the path to a recurring‑revenue SaaS model anchored in subscription fees and potential usage‑based add‑ons.
If the integration proceeds as planned, Medcast could transition from a niche ed‑tech provider to a core component of the clinical software stack, opening cross‑sell opportunities and laying the groundwork for future expansion into other specialties or regional markets.
Why It Matters
For Medcast, the infusion of capital and the Best Practice partnership turn a promising AI prototype into a market‑ready SaaS offering. The integration will likely shift Medcast’s revenue mix toward higher‑margin subscription contracts tied to practice‑management licenses, improving net revenue retention and providing a clearer path to scaling ARR. Competitors in the Australian health‑tech space—particularly those relying on generic large‑language models—will now face a product that combines localized content, onshore data residency, and a built‑in distribution channel, raising the bar for trust and adoption.
Best Practice gains a differentiated AI layer that can be bundled with its existing suite, strengthening its value proposition against global EMR vendors. The move also signals to other regional software firms that strategic equity stakes in niche AI providers can accelerate product differentiation without building technology from scratch. In the broader Australian market, the deal may prompt additional venture capital to target AI‑enabled clinical tools that prioritize compliance and local data governance.
Key Points
- Medcast raised US$5.4 million in a venture round led by Best Practice Software.
- The funds will be used to grow technology and clinical teams and to integrate MedLuma with practice‑management software.
- MedLuma is positioned as an AI copilot that surfaces Australian‑specific clinical guidelines with citation support.
- Best Practice’s investment deepens an existing collaboration and provides immediate distribution to Australian GPs.
- Medcast has served over 100,000 healthcare professionals since its 2013 launch.
Analysis
The $5.4 million raise places Medcast in the upper tier of early‑stage health‑tech AI startups that are attracting strategic corporate capital. While the round’s valuation was not disclosed, comparable Australian SaaS ventures typically command 8‑12x forward‑looking ARR at Series A, suggesting Medcast could be valued in the $40‑$70 million range if it can translate its AI engine into recurring subscription revenue. The partnership with Best Practice accelerates go‑to‑market velocity, a critical factor in a market where clinicians prioritize data sovereignty and guideline alignment. For investors, the deal underscores a growing appetite for AI solutions that are tightly integrated with existing clinical workflows rather than stand‑alone search tools. Operators should note that embedding AI into practice‑management platforms can boost expansion revenue and improve net revenue retention, as clinicians are more likely to adopt add‑ons that sit within their daily workflow. The Australian health‑tech ecosystem may see a wave of similar strategic investments as software vendors seek to differentiate through localized, compliant AI capabilities, potentially tightening the competitive moat around incumbents that secure such partnerships early.